Immunophilins and thrombotic disorders

Current Medicinal Chemistry

Volumn 18, Issue 35, 2011, Pages 5414-5423

  Lopez, E ^a   Rosado, J A ^a   Redondo, P C ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Cyclophilins; FKBPs; Immunophilins; Platelets; Thrombotic disorders

Indexed keywords

ALISPORIVIR; ASCOMYCIN; CHAPERONE; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYCLOSPORIN G; EVEROLIMUS; IMMUNOPHILIN; OXECLOSPORIN; PIMECROLIMUS; SANGLIFEHRIN A; TACROLIMUS; TEMSIROLIMUS; VOCLOSPORIN; ZOTAROLIMUS;

ARTICLE; CALCIUM HOMEOSTASIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; THROMBOSIS;

BLOOD PLATELETS; CYCLOSPORINE; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; PLATELET COUNT; THROMBOSIS;

EID: 82255195322     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798194405     Document Type: Article

References (149)

1. Fischer, G.; Bang, H.; Mech, C., [Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides]. Biomed Biochim Acta, 1984, 43, (10), 1101-1111. (Pubitemid 15221717)
2. Rulten, S.; Thorpe, J.; Kay, J., Identification of eukaryotic parvulin homologues: a new subfamily of peptidylprolyl cis-trans isomerases. Biochem Biophys Res Commun, 1999, 259, (3), 557-562. (Pubitemid 29335572)
3. Rahfeld, J. U.; Rucknagel, K. P.; Schelbert, B.; Ludwig, B.; Hacker, J.; Mann, K.; Fischer, G., Confirmation of the existence of a third family among peptidyl-prolyl cis/trans isomerases. Amino acid sequence and recombinant production of parvulin. FEBS Lett, 1994, 352, (2), 180-184. (Pubitemid 24298414)
4. Fischer, G.; Wittmann-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F. X., Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature, 1989, 337, (6206), 476-478.
5. Siekierka, J. J.; Staruch, M. J.; Hung, S. H.; Sigal, N. H., FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol, 1989, 143, (5), 1580-1583. (Pubitemid 19217422)
6. Adams, B.; Musiyenko, A.; Kumar, R.; Barik, S., A novel class of dualfamily immunophilins. J Biol Chem, 2005, 280, (26), 24308-24314.
7. Barik, S., Immunophilins: for the love of proteins. Cell Mol Life Sci, 2006, 63, (24), 2889-2900. (Pubitemid 46072296)
8. Chambraud, B.; Belabes, H.; Fontaine-Lenoir, V.; Fellous, A.; Baulieu, E. E., The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J, 2007, 21, (11), 2787-2797. (Pubitemid 47372746)
9. Ho, S.; Clipstone, N.; Timmermann, L.; Northrop, J.; Graef, I.; Fiorentino, D.; Nourse, J.; Crabtree, G. R., The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol, 1996, 80, (3 Pt 2), S40-45.
10. Puzik, A.; Schultz, C.; Iblher, P.; Muller-Steinhardt, M.; Hartel, C., Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr, 2007, 96, (10), 1483-1489. (Pubitemid 47416444)
11. Paquette, L. A.; Duan, M.; Konetzki, I.; Kempmann, C., A convergent threecomponent total synthesis of the powerful immunosuppressant (-) - sanglifehrin a. J Am Chem Soc, 2002, 124, (16), 4257-4270. (Pubitemid 34441559)
12. Nicolaou, K. C.; Xu, J.; Murphy, F.; Barluenga, S.; Baudoin, O.; Wei, H.; Gray, D. L.; Ohshima, T., Total Synthesis of Sanglifehrin A. Angew Chem Int Ed Engl, 1999, 38, (16), 2447-2451. (Pubitemid 29399590)
13. Hartel, C.; Rupp, J.; Iblher, P.; Puzik, A.; Osthues, I.; Schultz, C.; Muller-Steinhardt, M., Immunomodulatory effects of Sanglifehrin A in the innate and acquired immune response of neonatal whole blood cells. Immunobiology, 2009, 214, (3), 235-243.
14. Clarke, S. J.; McStay, G. P.; Halestrap, A. P., Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem, 2002, 277, (38), 34793-34799.
15. Javadov, S.; Karmazyn, M.; Escobales, N., Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther, 2009, 330, (3), 670-678.
16. Fehr, T.; Kallen, J.; Oberer, L.; Sanglier, J. J.; Schilling, W., Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. J Antibiot (Tokyo), 1999, 52, (5), 474-479. (Pubitemid 29271617)
17. Gregory, M. A.; Bobardt, M.; Obeid, S.; Chatterji, U.; Coates, N. J.; Foster, T.; Gallay, P.; Leyssen, P.; Moss, S. J.; Neyts, J.; Nur, E. A. M.; Paeshuyse, J.; Piraee, M.; Suthar, D.; Warneck, T.; Zhang, M. Q.; Wilkinson, B., Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. Antimicrob Agents Chemother, 2011, 55, (5), 1975-1981.
18. Andexer, J. N.; Kendrew, S. G.; Nur-e-Alam, M.; Lazos, O.; Foster, T. A.; Zimmermann, A. S.; Warneck, T. D.; Suthar, D.; Coates, N. J.; Koehn, F. E.; Skotnicki, J. S.; Carter, G. T.; Gregory, M. A.; Martin, C. J.; Moss, S. J.; Leadlay, P. F.; Wilkinson, B., Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate. Proc Natl Acad Sci U S A, 2011, 108, (12), 4776-4781.
19. Kozany, C.; Marz, A.; Kress, C.; Hausch, F., Fluorescent probes to characterise FK506-binding proteins. Chembiochem, 2009, 10, (8), 1402-1410.
20. Pruschy, M. N.; Spencer, D. M.; Kapoor, T. M.; Miyake, H.; Crabtree, G. R.; Schreiber, S. L., Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. Chem Biol, 1994, 1, (3), 163-172.
21. Zhao, T.; Newman, P. J., Integrin activation by regulated dimerization and oligomerization of platelet endothelial cell adhesion molecule (PECAM)-1 from within the cell. J Cell Biol, 2001, 152, (1), 65-73. (Pubitemid 32102437)
22. Gross, A.; Jockel, J.; Wei, M. C.; Korsmeyer, S. J., Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J, 1998, 17, (14), 3878-3885. (Pubitemid 28333974)
23. Luik, R. M.; Wang, B.; Prakriya, M.; Wu, M. M.; Lewis, R. S., Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature, 2008, 454, (7203), 538-542.
24. Daum, S.; Schumann, M.; Mathea, S.; Aumuller, T.; Balsley, M. A.; Constant, S. L.; de Lacroix, B. F.; Kruska, F.; Braun, M.; Schiene-Fischer, C., Isoform-specific inhibition of cyclophilins. Biochemistry, 2009, 48, (26), 6268-6277.
25. Arber, S.; Krause, K. H.; Caroni, P., s-cyclophilin is retained intracellularly via a unique COOH-terminal sequence and colocalizes with the calcium storage protein calreticulin. J Cell Biol, 1992, 116, (1), 113-125.
26. Allain, F.; Durieux, S.; Denys, A.; Carpentier, M.; Spik, G., Cyclophilin B binding to platelets supports calcium-dependent adhesion to collagen. Blood, 1999, 94, (3), 976-983. (Pubitemid 29361829)
27. Coppinger, J. A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J. P.; Cahill, D. J.; Emili, A.; Fitzgerald, D. J.; Maguire, P. B., Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood, 2004, 103, (6), 2096-2104. (Pubitemid 38326225)
28. Xiao, Z.; Li, C.; Shan, J.; Luo, L.; Feng, L.; Lu, J.; Li, S.; Long, D.; Li, Y., Mechanisms of Renal Cell Apoptosis Induced by Cyclosporine A: A Systematic Review of in vitro Studies. Am J Nephrol, 2011, 33, (6), 558-566.
29. Jobe, S. M.; Wilson, K. M.; Leo, L.; Raimondi, A.; Molkentin, J. D.; Lentz, S. R.; Di Paola, J., Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood, 2008, 111, (3), 1257-1265. (Pubitemid 351213408)
30. Liu, Z. J.; Italiano, J., Jr.; Ferrer-Marin, F.; Gutti, R.; Bailey, M.; Poterjoy, B.; Rimsza, L.; Sola-Visner, M., Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood, 2011, 117, (15), 4106-4117.
31. Babinska, A.; Markell, M. S.; Salifu, M. O.; Akoad, M.; Ehrlich, Y. H.; Kornecki, E., Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant, 1998, 13, (12), 3153-3159. (Pubitemid 28534723)
32. Moore, S. F.; Hunter, R. W.; Hers, I., mTORC2-mediated Akt Ser473 phosphorylation is not required for Akt1 activity in human platelets. J Biol Chem, 2011.
33. Guerriero, R.; Parolini, I.; Testa, U.; Samoggia, P.; Petrucci, E.; Sargiacomo, M.; Chelucci, C.; Gabbianelli, M.; Peschle, C., Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci, 2006, 119, (Pt 4), 744-752.
34. Raslova, H.; Baccini, V.; Loussaief, L.; Comba, B.; Larghero, J.; Debili, N.; Vainchenker, W., Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood, 2006, 107, (6), 2303-2310. (Pubitemid 43345548)
35. Giraudier, S.; Chagraoui, H.; Komura, E.; Barnache, S.; Blanchet, B.; LeCouedic, J. P.; Smith, D. F.; Larbret, F.; Taksin, A. L.; Moreau-Gachelin, F.; Casadevall, N.; Tulliez, M.; Hulin, A.; Debili, N.; Vainchenker, W., Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood, 2002, 100, (8), 2932-2940.
36. Bock, O.; Neusch, M.; Busche, G.; Mengel, M.; Kreipe, H., Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and nonneoplastic haematopoiesis. Eur J Haematol, 2004, 72, (4), 239-244. (Pubitemid 38406554)
37. Uchida, T.; Fujimori, F.; Tradler, T.; Fischer, G.; Rahfeld, J. U., Identification and characterization of a 14 kDa human protein as a novel parvulin-like peptidyl prolyl cis/trans isomerase. FEBS Lett, 1999, 446, (2-3), 278-282. (Pubitemid 29132743)
38. Mori, T.; Hidaka, M.; Lin, Y. C.; Yoshizawa, I.; Okabe, T.; Egashira, S.; Kojima, H.; Nagano, T.; Koketsu, M.; Takamiya, M.; Uchida, T., A dual inhibitor against prolyl isomerase Pin1 and cyclophilin discovered by a novel real-time fluorescence detection method. Biochem Biophys Res Commun, 2011, 406, (3), 439-443.
39. Kuhlewein, A.; Voll, G.; Hernandez Alvarez, B.; Kessler, H.; Fischer, G.; Rahfeld, J. U.; Gemmecker, G., Solution structure of Escherichia coli Par10: The prototypic member of the Parvulin family of peptidyl-prolyl cis/trans isomerases. Protein Sci, 2004, 13, (9), 2378-2387. (Pubitemid 39128858)
40. Carson, R.; McKnight, A. J.; Todd, S.; Liu, W. W.; Heggarty, S.; Craig, D.; McGuinness, B.; Irvine, G. B.; Passmore, A. P.; Johnston, J. A., Variation in RTN3 and PPIL2 genes does not influence platelet membrane beta-secretase activity or susceptibility to alzheimer's disease in the northern Irish population. Neuromolecular Med, 2009, 11, (4), 337-344.
41. 2+ channel in an FKBP12-dependent manner. J Biol Chem, 1999, 274, (46), 32603-32612. (Pubitemid 129535286)
42. Jayaraman, T.; Brillantes, A. M.; Timerman, A. P.; Fleischer, S.; Erdjument-Bromage, H.; Tempst, P.; Marks, A. R., FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem, 1992, 267, (14), 9474-9477.
43. 2+ dynamics and catecholamine release in acetylcholine-stimulated bovine adrenal chromaffin cells. J Pharmacol Sci, 2006, 101, (1), 40-51. (Pubitemid 43778736)
44. Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; Walensky, L. D.; Snyder, S. H., Immunophilin FK506 binding protein associated with inositol 1, 4, 5-trisphosphate receptor modulates calcium flux. Proc Natl Acad Sci U S A, 1995, 92, (5), 1784-1788.
45. Jayaraman, T.; Ondrias, K.; Ondriasova, E.; Marks, A. R., Regulation of the inositol 1, 4, 5-trisphosphate receptor by tyrosine phosphorylation. Science, 1996, 272, (5267), 1492-1494. (Pubitemid 26200002)
46. 2+ flux. Cell, 1995, 83, (3), 463-472.
47. Misra, U. K.; Gawdi, G.; Pizzo, S. V., Cyclosporin A inhibits inositol 1, 4, 5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages. J Immunol, 1998, 161, (11), 6122-6127. (Pubitemid 28535983)
48. Rosado, J. A.; Pariente, J. A.; Salido, G. M.; Redondo, P. C., SERCA2b activity is regulated by cyclophilins in human platelets. Arterioscler Thromb Vasc Biol, 2010, 30, (3), 419-425.
49. Fox, S. C.; Judge, H. M.; Allen, B. R.; Heptinstall, S., Platelet aggregation and intracellular calcium mobilisation responses are enhanced by cyclosporin A but not by pimecrolimus (SDZ ASM 981). Platelets, 2002, 13, (4), 213-218. (Pubitemid 34787731)
50. Wellington, K.; Spencer, C. M., Sdz asm 981. BioDrugs, 2000, 14, (6), 409-416. (Pubitemid 32105548)
51. 2+ compartments in the megakaryoblastic cell line MEG01. Biochim Biophys Acta, 2011, 1813, (8), 1483-1494.
52. Mignen, O.; Thompson, J. L.; Shuttleworth, T. J., Calcineurin directs the reciprocal regulation of calcium entry pathways in nonexcitable cells. J Biol Chem, 2003, 278, (41), 40088-40096. (Pubitemid 37248575)
53. Sinkins, W. G.; Goel, M.; Estacion, M.; Schilling, W. P., Association of immunophilins with mammalian TRPC channels. J Biol Chem, 2004, 279, (33), 34521-34529. (Pubitemid 39318080)
54. Lopez, E.; Salido, G. M.; Rosado, J. A.; Redondo, P. C., Immunophilins participate in the activation of store operated calcium entry by regulating calcineurin-dependent and-independent pathways in human platelets. British Journal of Pharmacology, 2001, under revision.
55. Shim, S.; Yuan, J. P.; Kim, J. Y.; Zeng, W.; Huang, G.; Milshteyn, A.; Kern, D.; Muallem, S.; Ming, G. L.; Worley, P. F., Peptidyl-prolyl isomerase FKBP52 controls chemotropic guidance of neuronal growth cones via regulation of TRPC1 channel opening. Neuron, 2009, 64, (4), 471-483.
56. Yuan, J. P.; Kiselyov, K.; Shin, D. M.; Chen, J.; Shcheynikov, N.; Kang, S. H.; Dehoff, M. H.; Schwarz, M. K.; Seeburg, P. H.; Muallem, S.; Worley, P. F., Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors. Cell, 2003, 114, (6), 777-789. (Pubitemid 37186771)
57. Huang, G. N.; Zeng, W.; Kim, J. Y.; Yuan, J. P.; Han, L.; Muallem, S.; Worley, P. F., STIM1 carboxyl-terminus activates native SOC., I (crac) and TRPC1 channels. Nat Cell Biol, 2006, 8, (9), 1003-1010. (Pubitemid 44314732)
58. 2+-ATPase by macrocyclic lactones and cyclosporin A. Biochem J, 2002, 366, (Pt 1), 255-263. (Pubitemid 34971825)
59. 2+ accumulation mechanisms. J Physiol, 2000, 525 Pt 3, 681-693. (Pubitemid 30426789)
60. Caporello, E.; Nath, A.; Slevin, J.; Galey, D.; Hamilton, G.; Williams, L.; Steiner, J. P.; Haughey, N. J., The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem, 2006, 98, (1), 146-155. (Pubitemid 43882940)
61. 2+ uptake into the endoplasmic reticulum and mitochondria. J Biol Chem, 2001, 276, (26), 23329-23340.
62. 2+-ATPase type 3 gene, ATP2A3, is regulated by the calcineurin/NFAT pathway in endothelial cells. Biochem J, 2006, 394, (Pt 1), 27-33. (Pubitemid 43259652)
63. 2+ pump. J Am Soc Nephrol, 2003, 14, (6), 1435-1442. (Pubitemid 36687044)
64. Guerini, D.; Wang, X.; Li, L.; Genazzani, A.; Carafoli, E., Calcineurin controls the expression of isoform 4CII of the plasma membrane Ca (2+) pump in neurons. J Biol Chem, 2000, 275, (5), 3706-3712. (Pubitemid 30083084)
65. Paszty, K.; Kovacs, T.; Lacabaratz-Porret, C.; Papp, B.; Enouf, J.; Filoteo, A. G.; Penniston, J. T.; Enyedi, A., Expression of hPMCA4b, the major form of the plasma membrane calcium pump in megakaryoblastoid cells is greatly reduced in mature human platelets. Cell Calcium, 1998, 24, (2), 129-135. (Pubitemid 28470430)
66. Dean, W. L., Role of platelet plasma membrane Ca-ATPase in health and disease. World J Biol Chem, 2010, 1, (9), 265-270.
67. Massol, N.; Lebeau, M. C.; Renoir, J. M.; Faber, L. E.; Baulieu, E. E., Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. Biochem Biophys Res Commun, 1992, 187, (3), 1330-1335.
68. 2+/calmodulin. EMBO J, 2005, 24, (14), 2688-2699. (Pubitemid 41076324)
69. Maestre-Martinez, M.; Haupt, K.; Edlich, F.; Jahreis, G.; Jarczowski, F.; Erdmann, F.; Fischer, G.; Lucke, C., New structural aspects of FKBP38 activation. Biol Chem, 2010, 391, (10), 1157-1167.
70. Pezzi, L.; Merat, D. L.; Winkler, M. A.; Cheung, W. Y., Calmodulindependent phosphatase preferentially dephosphorylates a 28 kDa protein in human platelets. Int J Biochem, 1989, 21, (7), 791-798. (Pubitemid 19188967)
71. Merat, D. L.; Hu, Z. Y.; Carter, T. E.; Cheung, W. Y., Subunit A of calmodulin-dependent protein phosphatase requires Mn2+ for activity. Biochem Biophys Res Commun, 1984, 122, (3), 1389-1396. (Pubitemid 14073574)
72. Tallant, E. A.; Cheung, W. Y., Activation of bovine brain calmodulindependent protein phosphatase by limited trypsinization. Biochemistry, 1984, 23, (5), 973-979.
73. Noto, T.; Furuichi, Y.; Ishiye, M.; Matsuoka, N.; Aramori, I.; Mutoh, S.; Yanagihara, T., Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat. Biol Pharm Bull, 2007, 30, (2), 313-317.
74. Garcia, E.; Stracher, A.; Jay, D., Calcineurin dephosphorylates the C-terminal region of filamin in an important regulatory site: a possible mechanism for filamin mobilization and cell signaling. Arch Biochem Biophys, 2006, 446, (2), 140-150. (Pubitemid 43234225)
75. Pandey, D.; Goyal, P.; Dwivedi, S.; Siess, W., Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. Blood, 2009, 114, (2), 415-424.
76. Rosado, J. A.; Jenner, S.; Sage, S. O., A role for the actin cytoskeleton in the initiation and maintenance of store-mediated calcium entry in human platelets. Evidence for conformational coupling. J Biol Chem, 2000, 275, (11), 7527-7533. (Pubitemid 30159649)
77. 2+-dependent dephosphorylation of cofilin that is independent of dense granule secretion and aggregation. Blood Cells Mol Dis, 2007, 38, (3), 269-279. (Pubitemid 46518177)
78. Nakajima, O.; Nakamura, F.; Yamashita, N.; Tomita, Y.; Suto, F.; Okada, T.; Iwamatsu, A.; Kondo, E.; Fujisawa, H.; Takei, K.; Goshima, Y., FKBP133: a novel mouse FK506-binding protein homolog alters growth cone morphology. Biochem Biophys Res Commun, 2006, 346, (1), 140-149. (Pubitemid 43865978)
79. Galigniana, M. D.; Radanyi, C.; Renoir, J. M.; Housley, P. R.; Pratt, W. B., Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J Biol Chem, 2001, 276, (18), 14884-14889.
80. Harrell, J. M.; Murphy, P. J.; Morishima, Y.; Chen, H.; Mansfield, J. F.; Galigniana, M. D.; Pratt, W. B., Evidence for glucocorticoid receptor transport on microtubules by dynein. J Biol Chem, 2004, 279, (52), 54647-54654. (Pubitemid 40053208)
81. Nolasco, L. H.; Gushiken, F. C.; Turner, N. A.; Khatlani, T. S.; Pradhan, S.; Dong, J. F.; Moake, J. L.; Vijayan, K. V., Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells. J Thromb Haemost, 2009, 7, (6), 1009-1018.
82. Weyrich, A. S.; Denis, M. M.; Schwertz, H.; Tolley, N. D.; Foulks, J.; Spencer, E.; Kraiss, L. W.; Albertine, K. H.; McIntyre, T. M.; Zimmerman, G. A., mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood, 2007, 109, (5), 1975-1983. (Pubitemid 46348195)
83. Serr, F.; Lauer, H.; Armann, B.; Ludwig, S.; Thiery, J.; Fiedler, M.; Ceglarek, U.; Tannapfel, A.; Uhlmann, D.; Hauss, J.; Witzigmann, H., Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemia-reperfusion injury. Am J Transplant, 2007, 7, (1), 48-56. (Pubitemid 44952855)
84. Wu, Q.; Huang, K. S.; Chen, M.; Huang, D. J., Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro. Platelets, 2009, 20, (6), 428-431.
85. Oh, W. J.; Jacinto, E., mTOR complex 2 signaling and functions. Cell Cycle, 2011, 10, (14).
86. Garcia-Martinez, J. M.; Moran, J.; Clarke, R. G.; Gray, A.; Cosulich, S. C.; Chresta, C. M.; Alessi, D. R., Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J, 2009, 421, (1), 29-42.
87. Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C.; Guichard, S.; Pass, M., AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70, (1), 288-298.
88. Thoreen, C. C.; Kang, S. A.; Chang, J. W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L. J.; Sim, T.; Sabatini, D. M.; Gray, N. S., An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem, 2009, 284, (12), 8023-8032.
89. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M., Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol, 2009, 7, (2), e38.
90. Bhagwat, S. V.; Gokhale, P. C.; Crew, A. P.; Cooke, A.; Yao, Y.; Mantis, C.; Kahler, J.; Workman, J.; Bittner, M.; Dudkin, L.; Epstein, D. M.; Gibson, N. W.; Wild, R.; Arnold, L. D.; Houghton, P. J.; Pachter, J. A., Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin. Mol Cancer Ther, 2011.
91. Schenone, S.; Brullo, C.; Musumeci, F.; Radi, M.; Botta, M., ATP-Competitive Inhibitors of mTOR: An Update. Curr Med Chem, 2011.
92. Drayer, A. L.; Olthof, S. G.; Vellenga, E., Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells, 2006, 24, (1), 105-114.
93. Bluteau, D.; Lordier, L.; Di Stefano, A.; Chang, Y.; Raslova, H.; Debili, N.; Vainchenker, W., Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost, 2009, 7 Suppl 1, 227-234.
94. Borel, J. F.; Feurer, C.; Gubler, H. U.; Stahelin, H., Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 1976, 6, (4), 468-475.
95. Calne, R. Y.; White, D. J.; Pentlow, B. D.; Rolles, K.; Syrakos, T.; Ohtawa, T.; Smith, D. P.; McMaster, P.; Evans, D. B.; Herbertson, B. M.; Thiru, S., Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc, 1979, 11, (1), 860-864. (Pubitemid 9174280)
96. Calne, R. Y.; Rolles, K.; White, D. J.; Thiru, S.; Evans, D. B.; McMaster, P.; Dunn, D. C.; Craddock, G. N.; Henderson, R. G.; Aziz, S.; Lewis, P., Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs:32 kidneys, 2 pancreases, and 2 livers. Lancet, 1979, 2, (8151), 1033-1036. (Pubitemid 10213970)
97. White, D. J.; Calne, R. Y.; Plumb, A., Mode of action of cyclosporin A: a new immunosuppressive agent. Transplant Proc, 1979, 11, (1), 855-859. (Pubitemid 9174279)
98. Taylor, J. E.; Porter, C.; Heptinstall, S.; McLaren, M.; Belch, J. J., Increased platelet activation in renal transplant patients. Platelets, 1999, 10, (4), 223-227. (Pubitemid 29391085)
99. Rosenthal, J.; Pawlowska, A.; Bolotin, E.; Cervantes, C.; Maroongroge, S.; Thomas, S. H.; Forman, S. J., Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer, 2011, 57, (1), 142-146.
100. Moake, J., Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol, 2009, 22, (4), 567-576.
101. Boctor, F. N., Tacrolimus (FK506) associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in lung transplant salvage with a plasmapheresis and cyclosporin. Egypt J Immunol, 2006, 13, (2), 95-99.
102. Fujino, M.; Kim, Y.; Ito, M., Intestinal thrombotic microangiopathy induced by FK506 in rats. Bone Marrow Transplant, 2007, 39, (6), 367-372. (Pubitemid 46403929)
103. Lin, C. C.; King, K. L.; Chao, Y. W.; Yang, A. H.; Chang, C. F.; Yang, W. C., Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol, 2003, 16, (4), 580-585. (Pubitemid 38120469)
104. Sindhi, R.; Seward, J.; Mazariegos, G.; Soltys, K.; Seward, L.; Smith, A.; Kosmach, B.; Venkataramanan, R., Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant, 2005, 9, (3), 391-397. (Pubitemid 40780373)
105. Imbasciati, E.; Bucci, R.; Barbisoni, F.; Borlandelli, S.; Corradi, B.; Cosci, P.; Farina, M.; Mandolfo, S., [Acute renal failure and thrombotic microangiopathy (TM)]. G Ital Nefrol, 2003, 20, (3), 285-297.
106. Said, T.; Al-Otaibi, T.; Al-Wahaib, S.; Francis, I.; Nair, M. P.; Halim, M. A.; El-Sayed, A.; Nampoory, M. R., Posttransplantation calcineurin inhibitorinduced hemolytic uremic syndrome: single-center experience. Transplant Proc, 2010, 42, (3), 814-816.
107. Fernandes, J. B.; Naik, U. P.; Markell, M. S.; Kornecki, E., Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation. Cell Mol Biol Res, 1993, 39, (3), 265-274. (Pubitemid 23338390)
108. Suehiro, A.; Sawada, A.; Hasegawa, Y.; Takatsuka, H.; Higasa, S.; Kakishita, E., Enhancement by cyclosporine A and tacrolimus of serotonininduced formation of small platelet aggregation. Bone Marrow Transplant, 2002, 29, (2), 107-111. (Pubitemid 34144841)
109. Graff, J.; Klinkhardt, U.; Harder, S.; Wegert, W.; Lenz, T.; Scheuermann, E. H.; Gossmann, J., Immunosuppressive therapy regimen and platelet activation in renal transplant patients. Clin Pharmacol Ther, 2002, 72, (4), 411-418. (Pubitemid 35178867)
110. Klein, B. C.; Bach, D.; Rehfeld, I.; Kirchhoff, E.; Hohlfeld, T.; Schror, K.; Scharf, R.; Grabensee, B., Influence of mycophenolic acid and FK-506 on human platelet activation in vitro. Kidney Blood Press Res, 2000, 23, (2), 119-124. (Pubitemid 30175631)
111. Sahin, G.; Akay, O. M.; Kus, E.; Bal, C.; Yalcin, A. U.; Gulbas, Z., Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients. Ren Fail, 2009, 31, (2), 111-117.
112. Jespersen, B.; Thiesson, H. C.; Henriksen, C.; Therland, K.; Falk, C.; Poulsen, T.; Fogh, B.; Madsen, K.; Walther, S.; Jensen, B. L., Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrol Dial Transplant, 2009, 24, (5), 1644-1655.
113. Brattstrom, C.; Sawe, J.; Tyden, G.; Herlenius, G.; Claesson, K.; Zimmerman, J.; Groth, C. G., Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit, 1997, 19, (4), 397-406. (Pubitemid 28074035)
114. Kovarik, J. M.; Hsu, C. H.; McMahon, L.; Berthier, S.; Rordorf, C., Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther, 2001, 70, (3), 247-254. (Pubitemid 32868488)
115. Aulestia, F. J.; Redondo, P. C.; Rodriguez-Garcia, A.; Rosado, J. A.; Salido, G. M.; Alonso, M. T.; Garcia-Sancho, J., Two distinct calcium pools in the endoplasmic reticulum of HEK-293T cells. Biochem J, 2011, 435, (1), 227-235.
116. Chandrasekera, C. P.; Lytton, J., Inhibition of human SERCA3 by PL/IM430. Molecular analysis of the interaction. J Biol Chem, 2003, 278, (14), 12482-12488. (Pubitemid 36800236)
117. Munch, G.; Bolck, B.; Karczewski, P.; Schwinger, R. H., Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium. J Mol Cell Cardiol, 2002, 34, (3), 321-334. (Pubitemid 37162424)
118. Thiel, G.; Bock, A.; Landmann, J.; Mihatsch, M., [Complications of immunosuppression]. Klin Monbl Augenheilkd, 1993, 202, (5), 479-484. (Pubitemid 23236343)
119. Potier, M.; Wolf, A.; Cambar, J., Comparative study of cyclosporin A, cyclosporin G, and the novel cyclosporin derivative IMM 125 in isolated glomeruli and cultured rat mesangial cells: a morphometric analysis. Nephrol Dial Transplant, 1998, 13, (6), 1406-1411. (Pubitemid 28254314)
120. Grub, S.; Trommer, W. E.; Wolf, A., Role of antioxidants in the O-hydroxyethyl-D-(Ser) 8-cyclosporine A (SDZ IMM125)-induced apoptosis in rat hepatocytes. Biochem Pharmacol, 2002, 64, (12), 1725-1736. (Pubitemid 35351579)
121. Puyang, X.; Poulin, D. L.; Mathy, J. E.; Anderson, L. J.; Ma, S.; Fang, Z.; Zhu, S.; Lin, K.; Fujimoto, R.; Compton, T.; Wiedmann, B., Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother, 2010, 54, (5), 1981-1987.
122. Wissing, E. R.; Millay, D. P.; Vuagniaux, G.; Molkentin, J. D., Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord, 2010, 20, (11), 753-760.
123. Damaso, C. R.; Moussatche, N., Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. J Gen Virol, 1998, 79(Pt 2), 339-346. (Pubitemid 28048438)
124. Xu, Q.; Leiva, M. C.; Fischkoff, S. A.; Handschumacher, R. E.; Lyttle, C. R., Leukocyte chemotactic activity of cyclophilin. J Biol Chem, 1992, 267, (17), 11968-11971.
125. Kuglstatter, A.; Mueller, F.; Kusznir, E.; Gsell, B.; Stihle, M.; Thoma, R.; Benz, J.; Aspeslet, L.; Freitag, D.; Hennig, M., Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). Acta Crystallogr D Biol Crystallogr, 2011, 67, (Pt 2), 119-123.
126. Birsan, T.; Dambrin, C.; Freitag, D. G.; Yatscoff, R. W.; Morris, R. E., The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int, 2005, 17, (12), 767-771. (Pubitemid 41187416)
127. Graham-Brown, R. A.; Grassberger, M., Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract, 2003, 57, (4), 319-327. (Pubitemid 36700718)
128. Lampropoulos, C. E.; D'Cruz, D. P., Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag, 2010, 6, 95-101.
129. Gisondi, P.; Ellis, C. N.; Girolomoni, G., Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract, 2005, 59, (8), 969-974.
130. Gupta, A. K.; Chow, M., Pimecrolimus: a review. J Eur Acad Dermatol Venereol, 2003, 17, (5), 493-503. (Pubitemid 37138884)
131. Marx, S. O.; Jayaraman, T.; Go, L. O.; Marks, A. R., Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res, 1995, 76, (3), 412-417.
132. Baughman, G.; Wiederrecht, G. J.; Campbell, N. F.; Martin, M. M.; Bourgeois, S., FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol, 1995, 15, (8), 4395-4402.
133. Carreras, C. W.; Fu, H.; Santi, D. V., An FKBP12 binding assay based upon biotinylated FKBP12. Anal Biochem, 2001, 298, (1), 57-61. (Pubitemid 33030121)
134. Liu, J.; Albers, M. W.; Wandless, T. J.; Luan, S.; Alberg, D. G.; Belshaw, P. J.; Cohen, P.; MacKintosh, C.; Klee, C. B.; Schreiber, S. L., Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry, 1992, 31, (16), 3896-3901.
135. Lyson, T.; Ermel, L. D.; Belshaw, P. J.; Alberg, D. G.; Schreiber, S. L.; Victor, R. G., Cyclosporine-and FK506-induced sympathetic activation correlates
136. Holsinger, L. J.; Spencer, D. M.; Austin, D. J.; Schreiber, S. L.; Crabtree, G. R., Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A, 1995, 92, (21), 9810-9814.
137. Fujine, K.; Ueda, H.; Hino, M.; Fujii, T., FR252921, a novel immunosuppressive agent isolated from Pseudomonas fluorescens no. 408813 III. In vivo activities. J Antibiot (Tokyo), 2003, 56, (2), 68-71. (Pubitemid 36372786)
138. Maestre-Martinez, M.; Edlich, F.; Jarczowski, F.; Weiwad, M.; Fischer, G.; Lucke, C., Solution structure of the FK506-binding domain of human FKBP38. J Biomol NMR, 2006, 34, (3), 197-202.
139. Edlich, F.; Weiwad, M.; Wildemann, D.; Jarczowski, F.; Kilka, S.; Moutty, M. C.; Jahreis, G.; Lucke, C.; Schmidt, W.; Striggow, F.; Fischer, G., The specific FKBP38 inhibitor N-(N', N'-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem, 2006, 281, (21), 14961-14970. (Pubitemid 43855200)
140. Anandappa, G.; Hollingdale, A.; Eisen, T., Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag Res, 2010, 2, 61-70.
141. Schuurman, H. J.; Cottens, S.; Fuchs, S.; Joergensen, J.; Meerloo, T.; Sedrani, R.; Tanner, M.; Zenke, G.; Schuler, W., SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation, 1997, 64, (1), 32-35. (Pubitemid 27327196)
142. Samad, N.; Younes, A., Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther, 2010, 3, 167-178.
143. Chen, Y. W.; Smith, M. L.; Sheets, M.; Ballaron, S.; Trevillyan, J. M.; Burke, S. E.; Rosenberg, T.; Henry, C.; Wagner, R.; Bauch, J.; Marsh, K.; Fey, T. A.; Hsieh, G.; Gauvin, D.; Mollison, K. W.; Carter, G. W.; Djuric, S. W., Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol, 2007, 49, (4), 228-235. (Pubitemid 46626015)
144. Buellesfeld, L.; Grube, E., ABT-578-eluting stents. The promising successor of sirolimus-and paclitaxel-eluting stent concepts? Herz, 2004, 29, (2), 167-170. (Pubitemid 38495890)
145. Ruan, B.; Pong, K.; Jow, F.; Bowlby, M.; Crozier, R. A.; Liu, D.; Liang, S.; Chen, Y.; Mercado, M. L.; Feng, X.; Bennett, F.; von Schack, D.; McDonald, L.; Zaleska, M. M.; Wood, A.; Reinhart, P. H.; Magolda, R. L.; Skotnicki, J.; Pangalos, M. N.; Koehn, F. E.; Carter, G. T.; Abou-Gharbia, M.; Graziani, E. I., Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A, 2008, 105, (1), 33-38.
146. Boeckeler, K.; Rosse, C.; Howell, M.; Parker, P. J., Manipulating signal delivery - plasma-membrane ERK activation in aPKC-dependent migration. J Cell Sci, 2010, 123, (Pt 16), 2725-2732.
147. Chong, H.; Ruchatz, A.; Clackson, T.; Rivera, V. M.; Vile, R. G., A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther, 2002, 5, (2), 195-203. (Pubitemid 34144836)
148. Indraccolo, S.; Moserle, L.; Tisato, V.; Gola, E.; Minuzzo, S.; Roni, V.; Persano, L.; Chieco-Bianchi, L.; Amadori, A., Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors. Gene Ther, 2006, 13, (12), 953-965. (Pubitemid 43827337)
149. Chen, J.; Miller, E. M.; Gallo, K. A., MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene, 2010, 29, (31), 4399-4411.